Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series - Scorecard - MDSpire

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • By

  • Avinash Chandu Nanwani

  • Jose Carlos De la Flor Merino

  • Elena Jiménez Mayor

  • Juan Daniel Díaz García

  • Celia Rodríguez Tudero

  • Arturo Villalobos Navarro

  • Esperanza Moral Berrio

  • Adriana Puente García

  • Jesus Hernández Vaquero

  • June 22, 2026

  • 0 min

Share

Clinical Scorecard: Inclisiran for Patients with Advanced Chronic Kidney Disease (Stages G4–G5 Non-Dialysis): Long-Term LDL-C Reduction and Positive Safety Outcomes at One-Year Follow-Up in a Real-World Cohort

At a Glance

CategoryDetail
ConditionAdvanced Chronic Kidney Disease (Stages G4–G5 Non-Dialysis)
Key MechanismsInclisiran inhibits hepatic PCSK9 synthesis, leading to reduced LDL-C levels.
Target PopulationPatients with advanced CKD stages G4–G5 not on dialysis and elevated LDL-C despite optimized therapy.
Care SettingTertiary care hospital

Key Highlights

  • Mean LDL-C reduction of 65.6% after one year.
  • 80% of patients achieved LDL-C < 70 mg/dl.
  • Renal function remained stable with no adverse events reported.
  • 27.4% reduction in median albuminuria observed.
  • Inclisiran administered every 6 months.

Guideline-Based Recommendations

Diagnosis

  • Patients should be diagnosed with advanced CKD based on KDIGO criteria.

Management

  • Inclisiran is recommended for patients with elevated LDL-C despite maximized lipid-lowering therapy.

Monitoring & Follow-up

  • Lipid profile, renal function, and albuminuria should be assessed at baseline, 3–6 months, and 12 months.

Risks

  • Statin intolerance is common in this population, complicating lipid control.

Patient & Prescribing Data

10 adult patients with stage G4–G5 CKD not on dialysis.

Inclisiran shows marked LDL-C reduction and a favorable safety profile in this cohort.

Clinical Best Practices

  • Administer inclisiran at a dose of 284 mg subcutaneously on day 0, day 90, and every 6 months thereafter.
  • Ensure patients are receiving maximized nephroprotective therapy concurrently.

Related Resources & Content

Original Source(s)

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • by Avinash Chandu Nanwani, Jose Carlos De la Flor Merino, Elena Jiménez Mayor, Juan Daniel Díaz García, Celia Rodríguez Tudero, Arturo Villalobos Navarro, Esperanza Moral Berrio, Adriana Puente García, Jesus Hernández Vaquero

  • June 22, 2026

Related Content

Early aortic valve intervention versus clinical surveillance in patients with asymptomatic severe aortic stenosis: a systematic review and meta-analysis

Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis

Calcium dysregulation in diabetic cardiomyopathy & heart failure with preserved ejection fraction